Skip Navigation LinksHome > October 1, 2001 - Volume 28 - Issue 2 > Low Frequency of Severe Hepatotoxicity and Association With...
JAIDS Journal of Acquired Immune Deficiency Syndromes:
Articles: PDF Only

Low Frequency of Severe Hepatotoxicity and Association With HCV Coinfection in HIV-Positive Patients Treated With HAART.

Monforte, Antonella d'Arminio; Bugarini, Roberto; Pezzotti, Patrizio; De Luca, Andrea; Antinori, Andrea; Mussini, Cristina; Vigevani, Gian Marco; Tirelli, Umberto; Bruno, Raffaele; Gritti, Francesco; Piazza, Marcello; Chigiotti, Silvia; Chirianni, Antonio; De Stefano, Carlo; Pizzigallo, Eligio; Perrella, Oreste; Moroni, Mauro; for the ICONA Study Group

Collapse Box


Background: Highly active antiretroviral therapy (HAART) is strongly effective in reducing morbidity and mortality in HIV-1-positive individuals. Its main drawback is the potential toxicity. Data on the frequency and determinants of severe hepatotoxicity in a clinical setting are still sparse.

Methods: This is a prospective study of HIV-1-positive individuals with known HBsAg and HCV-Ab serology. The study end point was progression to alanine aminotransferase (ALT) levels >=200 IU/L after HAART initiation. Cumulative probability of progression to this end point was estimated by the Kaplan-Meier method. Crude and adjusted hazard ratios (HR) were estimated by proportional hazards regression model.

Results: One thousand two hundred fifty-five patients were included. HBsAg was found in 91 (7.2%), HCV-Ab in 578 (46.5%) patients; almost all injection drug users (451 of 482; 93.6%) were HCV-Ab positive. Sixty-one individuals progressed to the end point with a probability of 7.9% (95% confidence interval [CI], 5.6-10.0) of progression at 24 months from starting. Independent factors predicting progression to the end point were baseline ALT levels (HR, 5.29; 95% CI, 3.24-8.65; every 10 IU/L higher), HCV-Ab positivity (HR, 4.01; 95% CI, 1.48-10.85) or both HBsAg and HCV Ab positivity (HR, 3.85, 95% CI, 1.01-14.61), and previous non-HAART therapy (HR, 1.84, 95% CI, 1.04-3.42). Patients receiving stavudine-containing regimens had a lower risk than those receiving zidovudine-containing regimens (HR, 0.30, 95% CI, 0.12-0.71).

Conclusions: There was a low risk of ALT >=200 IU/L in our cohort. Hepatitis C coinfection and elevated ALT levels at HAART initiation are important predictors of progression to ALT >=200 IU/L; stavudine-containing regimens were associated with a lower risk compared with zidovudine-containing regimens.

(C) 2001 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.